Results 201 to 210 of about 17,377,748 (367)
The COMBAT classification system, developed through multi‐omics integration, stratifies adult patients with B‐cell acute lymphoblastic leukemia(B‐ALL) into three molecular subtypes with distinct surface antigen patterns, immune landscape, methylation patterns, biological pathways and prognosis.
Yang Song+11 more
wiley +1 more source
Switching of supramolecular nanostructures at the solid-liquid interface: interplay of bias polarity and solution concentration. [PDF]
Jia B+5 more
europepmc +1 more source
On the Existence of Positive Decaying Entire Solutions for a Class of Sublinear Elliptic Equations [PDF]
Yasuhiro Furusho, Takaŝi Kusano
openalex +1 more source
Xinguang Zhang, Lishan Liu, Yonghong Wu
semanticscholar +1 more source
In patients treated with atezolizumab as a part of the MyPathway (NCT02091141) trial, pre‐treatment ctDNA tumor fraction at high levels was associated with poor outcomes (radiographic response, progression‐free survival, and overall survival) but better sensitivity for blood tumor mutational burden (bTMB).
Charles Swanton+17 more
wiley +1 more source
Preparation and validation of skim milk-based method for preservation of bacterial strain at resource-limited setup. [PDF]
Mukhida S, Chavan S, Pandya V, Pandya J.
europepmc +1 more source
Non‐thermal plasma treatment of melanoma cells induced epithelial‐mesenchymal transition (EMT) in a dose‐dependent fashion. This report highlights the critical need to further investigate potential adverse effects of non‐thermal plasma for cancer therapy and to optimize treatment parameters for clinical translation. Despite the promising results of non‐
Eline Biscop+10 more
wiley +1 more source
The rechargeable battery using uranium as an active material. [PDF]
Ouchi K, Ueno K, Watanabe M.
europepmc +1 more source
Un résultat de non-existence de solution positive pour une équation elliptique [PDF]
Xiaomin Zheng
openalex +1 more source
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed+8 more
wiley +1 more source